Recent Articles
Page 1 of 4
April 27, 2021
Immuneering Expands Board of Directors with Addition of Senior Biotechnology Executive Laurie Keating
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation (“Immuneering”) today announced the addition of Laurie Keating to its board of directors. Ms. Keating brings more than 25 years…
April 6, 2021
Immuneering Appoints Biren Amin, M.B.A., as Chief Financial Officer
CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the appointment of Biren Amin, M.B.A., as Chief Financial Officer. Mr. Amin comes to Immuneering from Jefferies Financial…
February 4, 2021
Disease Cancelling Technology Emulates Sound Cancelling Technology to Mute Cancer
In this article by Gail Dutton, our co-founder and CEO Ben Zeskind discusses Immuneering’s proprietary Disease Cancelling Technology platform, and our growing pipeline of medicines targeting signaling pathways that are…
January 19, 2021
Disease-cancelling drugs: Immuneering raises $62m in Series B round
In this article by Allie Nawrat, our co-founder and CEO Ben Zeskind discusses Immuneering’s recent financing of $62m, in an oversubscribed Series B round led by high-profile life science investors….
Immuneering secures $62M series B to advance tech-driven pipeline
In this article by Michael Fitzhugh, Immuneering co-founder and CEO Ben Zeskind discusses the company’s recent oversubscribed Series B financing, which raised a total of $62M to advance its Disease…
January 5, 2021
Immuneering Completes Oversubscribed $62 Million Series B Financing
Financing to support advancement of Immuneering’s lead drug programs targeting cancers driven by alterations in the RAS/MAPK pathway and pipeline development of earlier programs in neuroscience and immuno-oncology.
November 10, 2020
Biomarkers Show the Power of Contexualization
In this Genetic Engineering & Biotechnology News article by Richard A. Stein, Immuneering’s Head of Neuroscience J.L. Ross, Ph.D. discusses the company’s integration of biomarkers with bioinformatic, proteomic, and gene signature information…
October 26, 2020
Silencing gene expression to cure complex diseases
In this article by Zach Winn, Immuneering co-founder and CEO Ben Zeskind discusses his journey from MIT undergraduate to biotech entrepreneur. He speaks to the company’s decade-plus of experience helping…
August 11, 2020
Immuneering to Present at Oppenheimer’s Private Life Sciences Company Call Series
CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020. Immuneering…
June 25, 2020
Immuneering Enters Collaboration with Astex Pharmaceuticals to Identify Novel Therapeutic Targets in Central Nervous System Disorder Using Disease Cancelling Technology
CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a wholly owned subsidiary…
Page 1 of 4
